Business Context and Reporting Period
This Form 8-K Current Report was filed by Rexahn Pharmaceuticals, Inc. on August 30, 2018. The filing reports on corporate governance actions taken at a Special Meeting of Shareholders held on the same date. Note: The request metadata references "Opus Genetics, Inc.," but the filing text explicitly identifies the registrant as Rexahn Pharmaceuticals, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and capital structure amendments rather than financial performance.
Material Changes
- Authorized Share Increase: The Company amended its Amended and Restated Certificate of Incorporation to increase authorized common stock from 50,000,000 to 75,000,000 shares.
- Shareholder Approval: The amendment was approved by shareholders at the Special Meeting. On the record date, there were 31,751,939 shares issued, outstanding, and entitled to vote.
Voting Results and Management Commentary
The shareholder vote on the proposal to approve the Amendment was certified by the inspector of elections. There were no broker non-votes.
| Vote Category | Number of Shares |
|---|---|
| For | 18,657,754 |
| Against | 6,366,667 |
| Abstain | 1,538,204 |
The filing does not contain specific management commentary, guidance, outlook, or discussion of risks and contingencies beyond the procedural details of the amendment.
Investor Verification Checklist
- Verify the current number of authorized shares (75,000,000) in the Company's charter.
- Review the Definitive Proxy Statement filed on July 23, 2018, for detailed rationale behind the share increase.
- Confirm the impact of the increased authorized shares on potential future dilution or capital raising activities.
- Check subsequent filings for any actual issuance of shares from the newly authorized pool.